New Data Shed Further Light on HCV Protease Race
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Final Phase II data have set the stage for the ultimate chapter in a compelling race to develop the first hepatitis C protease inhibitor. These first-generation molecules - Vertex's telaprevir and Schering-Plough's boceprevir - are not perfect, but look likely to significantly improve HCV cure rates and establish shorter durations for difficult-to-take therapeutic regimens